Treatment of severe alcohol-toxic hepatitis. Comparative study between two therapeutic approaches: Sulfaodenosil-L-methionine (SAMe) vs SAMe plus metilprednisolone;Tratamiento de la hepatitis tóxica grave por alcohol. Estudio comparativo entre dos medidas terapéuticas: Sulfoadenosil-L-metionina (SAMe) vs SAMe más metilprednisolona

Medicina Interna de Mexico

Volumn 20, Issue 1, 2004, Pages 18-23

  Magallán, Alfredo Rodríguez ^a   Gómez, Roxana Martínez ^a   Ruíz, Eli García ^a   Irisson, Laura Zapata ^a   Guzmán, Carlos Pérez ^b  

^a HOSPITAL JUÁREZ DE MÉXICO   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Alcohol toxic hepatitis; Metilprednisolone; Sulfaodenosil L methionine; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; METHIONINE DERIVATIVE; METHYLPREDNISOLONE; SERUM ALBUMIN; SULFAODENOSIL LEVO METHIONINE; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MONOTHERAPY; PATIENT SATISFACTION; PROTHROMBIN TIME; TREATMENT OUTCOME;

EID: 35348876026     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33-42.
2. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, et al. Ethanol-inducible cytochrome P-4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993;10:447-52.
3. Díaz BA. Epidemiología del alcoholismo en México. Alcoholismo. México: Piensa, 1997; p:17.
4. Martínez SG, Rodríguez MA. Epidemiología de la cirrosis por alcohol en el Hospital Juárez de México. Rev HJ Mex 1994;61:72-74.
5. Maddrey WC. Alcoholic hepatitis: Clinicopathologic features and therapy. Semin Liver Dis 1988;8:91-102.
6. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-12.
7. Mathurin P, Duchatelle V, Ramond M, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847-53.
8. Mendenhall CL, Anderson S, Garcipont P. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxadrolone and prednisolone. N Engl J Med 1984;311:1464-27.
9. Orrego H, Blake JE, Blendis LM, et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987;317:1424-27.
10. Akriviadis EA, Steindel H, Pinto PC, Fong TL, Reynolds TB, Kanel G, et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990;99:811-8.
11. Feher J, Cornides A, Romany A, et al. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis. Hepatology 1987;5:224-31.
12. Colman JC, Morgan MY, Schener PJ, et al. Treatment of alcohol-related liver disease with cyanidanol-3: a randomized double-blind trial. Gut 1980;21:965.
13. Limuro Y, Ikejima K, Rose ML, et al. Nimodipine, a dibydropyridine-type calcium channel bloker, prevents alcoholic hepatitis caused by chronic intragastric ethanol exposure in the rat. Hepatology 1996;24:391-7.
14. Cirello NW, Zwas FR. Ursodeoxycholic acid: the treatment of chronic liver disease. Am J Gastroenterol 1994;89:1447-52.
15. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improved short-term survival in severe acute alcoholic hepatitis: a double-blind placebo control trial. Gastroenterology 2000;119:1637-48.
16. Timothy R, Morgan C and McClain J. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000;119:1787-90.
17. Imperiale TF, McCullogh AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? Ann Intern Med 1990;113:299-307.
18. Mato J, Alvarez L, Ortiz P, Pajares M. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265-80.
19. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407-15.
20. Frezza M, Terpin M. The use of S-adenosyl-L-methionine in the treatment of cholestatic disorders. Drug Invest 1992;4:101-8.
21. Barak AJ, Beckenhamer HC, Tuma DJ. S-adenosylmethionine generation of alcoholic fatty liver. Alcohol 1994;11:501-3.
22. Mato JM, Camara J, Fernández J, Caballeria Ll, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
23. Diaz Belmont A, Domínguez HR, Uribe A. Parenteral S-adenosylmethionine compared to placebo in the treatment of alcoholic liver disease (Spanish). A Med Int 1996;13:9-15.